242 related articles for article (PubMed ID: 11589921)
1. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data.
Parnetti L; Amenta F; Gallai V
Mech Ageing Dev; 2001 Nov; 122(16):2041-55. PubMed ID: 11589921
[TBL] [Abstract][Full Text] [Related]
2. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
[TBL] [Abstract][Full Text] [Related]
3. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent.
Traini E; Bramanti V; Amenta F
Curr Alzheimer Res; 2013 Dec; 10(10):1070-9. PubMed ID: 24156263
[TBL] [Abstract][Full Text] [Related]
4. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment.
Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
J Alzheimers Dis; 2014; 42 Suppl 3():S281-8. PubMed ID: 24898643
[TBL] [Abstract][Full Text] [Related]
5. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
Parnetti L; Mignini F; Tomassoni D; Traini E; Amenta F
J Neurol Sci; 2007 Jun; 257(1-2):264-9. PubMed ID: 17331541
[TBL] [Abstract][Full Text] [Related]
6. Effect of treatment with choline alphoscerate on hippocampus microanatomy and glial reaction in spontaneously hypertensive rats.
Tomassoni D; Avola R; Mignini F; Parnetti L; Amenta F
Brain Res; 2006 Nov; 1120(1):183-90. PubMed ID: 16989788
[TBL] [Abstract][Full Text] [Related]
7. Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial.
Salvadori E; Poggesi A; Donnini I; Rinnoci V; Chiti G; Squitieri M; Tudisco L; Fierini F; Melone A; Pescini F; Pantoni L
Aging Clin Exp Res; 2020 Mar; 32(3):449-457. PubMed ID: 31148099
[TBL] [Abstract][Full Text] [Related]
8. The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies.
Amenta F; Di Tullio MA; Tomassoni D
Clin Exp Hypertens; 2002; 24(7-8):697-713. PubMed ID: 12450245
[TBL] [Abstract][Full Text] [Related]
9. Effect of Treatment of the Cholinergic Precursor Choline Alphoscerate in Mild Cognitive Dysfunction: A Randomized Controlled Trial.
Carotenuto A; Andreone V; Amenta F; Traini E
Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929542
[No Abstract] [Full Text] [Related]
10. Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.
Sagaro GG; Traini E; Amenta F
J Alzheimers Dis; 2023; 92(1):59-70. PubMed ID: 36683513
[TBL] [Abstract][Full Text] [Related]
11. Revisiting choline alphoscerate profile: a new, perspective, role in dementia?
Scapicchio PL
Int J Neurosci; 2013 Jul; 123(7):444-9. PubMed ID: 23387341
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial.
Salvadori E; Poggesi A; Donnini I; Rinnoci V; Chiti G; Squitieri M; Tudisco L; Fierini F; Melone A; Pescini F; Pantoni L
Drugs Aging; 2021 Jun; 38(6):481-491. PubMed ID: 33855653
[TBL] [Abstract][Full Text] [Related]
13. Quantitative electroencephalography changes in patients with mild cognitive impairment after choline alphoscerate administration.
Han SH; Chul Youn Y
J Clin Neurosci; 2022 Aug; 102():42-48. PubMed ID: 35714391
[TBL] [Abstract][Full Text] [Related]
14. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.
Fioravanti M; Yanagi M
Cochrane Database Syst Rev; 2004; (2):CD000269. PubMed ID: 15106147
[TBL] [Abstract][Full Text] [Related]
15. The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.
Carotenuto A; Rea R; Traini E; Fasanaro AM; Ricci G; Manzo V; Amenta F
J Alzheimers Dis; 2017; 56(2):805-815. PubMed ID: 28035924
[TBL] [Abstract][Full Text] [Related]
16. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.
Fioravanti M; Yanagi M
Cochrane Database Syst Rev; 2000; (2):CD000269. PubMed ID: 10796523
[TBL] [Abstract][Full Text] [Related]
17. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats.
Tayebati SK; Di Tullio MA; Tomassoni D; Amenta F
J Neurol Sci; 2009 Aug; 283(1-2):187-94. PubMed ID: 19304299
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?
Amenta F; Parnetti L; Gallai V; Wallin A
Mech Ageing Dev; 2001 Nov; 122(16):2025-40. PubMed ID: 11589920
[TBL] [Abstract][Full Text] [Related]
20. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission.
Amenta F; Tayebati SK; Vitali D; Di Tullio MA
Mech Ageing Dev; 2006 Feb; 127(2):173-9. PubMed ID: 16297435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
